Brief: Surface Oncology Presents Preclinical Data On Lead Clinical Programs
09/11/2021 13:11
Nov 9 (Reuters) - Surface Oncology Inc SURF.O :
* PRECLINICAL DATA SUPPORTING THERAPEUTIC POTENTIAL OF
SURFACE
ONCOLOGY’S LEAD CLINICAL PROGRAMS, SRF617 AND SRF388, PRESENTED
AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2021 ANNUAL MEETING
Source text for Eikon: ID:nGNX8Xr5ql
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing